Navigation Links
BellBrook Labs Seeking Partners to Accelerate Commercialization of Innovative HTS Assay Technologies
Date:11/20/2013

Madison, WI (PRWEB) November 20, 2013

BellBrook labs, an innovative developer of drug discovery tools, is seeking out collaborative scientific and commercial partners in cases where further development or commercialization of a technology is outside of the company’s core capabilities. The company develops technologies for both cellular and biochemical HTS assays. The company’s iuvo™ microchannel array platform, developed with expert engineering, microfluidic and microfabrication capabilities, is a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology. The company’s Transcreener® HTS enzyme assays rely on proprietary immunodetection reagents to enable screening of thousands of different enzymes, including validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. The partnering portfolio includes cutting-edge drug discovery tools for chemotaxis assays, invasion assays, and assays for GPCR related targets. Two examples of technologies available for partnering are described below and detailed descriptions of the entire portfolio are available on BellBrook’s new Partnering webpage.

The CellWasher Plate is a multiwell plate with proprietary modifications to the wells that protect cells from liquid flow and enable the use of full immunocytochemistry protocols and other assays with multiple wash steps with greater than 90% retention of even the most non-adherent cells. Prototypes have been tested at Pharma and life science research companies, and are ready for final design optimization and full scale manufacturing.

BellBrook’s RGScreen assay is the only HTS -ready assay method for measuring Regulaor of G Protein Signaling (RGS) protein catalytic activity. The most direct way to detect RGS function is by measuring the increased GTPase activity of the associated Galpha protein. However, the GTPase activity of isolated Galpha proteins is limited by GDP dissociation, so RGS GAP activity cannot be measured using simple biochemical assays. Bellbrook’s novel RGScreen™ platform overcomes this kinetic constraint by using proprietary Galpha protein variants with altered GTP hydrolysis and GDP dissociation rates that enable detection of RGS GAP activity using the Transcreener® GDP Assay.

About BellBrook Labs. BellBrook Labs is a private, R&D driven company dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions for enzymes and phenotypic assays. The company’s products, including Transcreener® HTS enzyme assays and iuvo™ Microconduit Array plates are used by all of the major pharmaceutical companies and are available directly from BellBrook Labs or from their international distribution partners. For more information on any of these technologies or to discuss partnering opportunities, contact BellBrook Labs: @info.bellbrooklabs.com.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11345539.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BellBrook Labs Launches New Turn Key Methyltransferase Assay Kit for Oncogenic Histone Methyltransferase EZH2
2. BellBrook Labs Launches Second Generation Transcreener EPIGEN Methyltransferase Assay to Acclerate Epigenetic Drug Discovery
3. BellBrook Labs and Tecan Offer Webinar on Screening Epigenetic Targets
4. BellBrook Labs Launches Four New Turn-Key Methyltransferase Assay Kits
5. BellBrook Labs and BMG Labtech to Offer Webinar on Integrated Platform for Screening Kinases and Methyltransferases
6. BellBrook Labs Strengthens Ties with Cambio for Distribution of Transcreener HTS Assays in the UK
7. Foundation For the NIH Joins NIH In Seeking Proposals to Study Sports-Related Brain Injuries
8. The BioVoyage Institute is seeking the help of corporations, organizations, institutions, communities and individuals to help with bioscience and biotechnology education
9. Quantum Cures Announces Breakthrough Approach for Researchers Seeking Cures for Orphan and Rare Diseases
10. Chemical Publishing Company Seeking Authors for Titles on Waste Water Treatment, Ion Exchange, Reverse Osmosis, and Water Management for Shale Formation Gas Drilling
11. Chemical Publishing Company Seeking Authors for Definitive Title on Hydraulic Fracturing or Shale Gas Fracturing Technology, Fracking and Natural Gas Recovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life Sciences ... the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan and ... presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree ... products targeting the needs of consumers who are incorporating medical marijuana into their ... Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
Breaking Biology News(10 mins):